Trimethobenzamide Hydrochloride

Trade Names:
Tigan
- Capsules 300 mg
- Injection 100 mg/mL

Pharmacology

Feedback for Trimethobenzamide Hydrochloride As a treatment for... Avg User Ratings [?] Nausea/Vomiting 10 1 comments  Rate it! Compare with other drugs.

Believed to directly affect medullary chemoreceptor trigger zone to inhibit nausea.

Pharmacokinetics

Absorption

Following IM administration, T _max is 30 min. After PO administration T _max is 45 min. 300 mg oral capsules are equivalent to 200 mg IM. The bioavailability of the capsule formulation compared with the solution is 100%.

Elimination

Trimethobenzamide t _½ is 7 to 9 h.

Indications and Usage

Prevention and treatment of nausea and vomiting.

Contraindications

Hypersensitivity to benzocaine or other local anesthetics. Suppositories contraindicated in newborns or premature infants; parenteral use contraindicated in children.

Dosage and Administration

PO 250 mg 3 to 4 times daily. PR 200 mg 3 to 4 times daily. IM 200 mg 3 to 4 times daily.

PO 100 to 200 mg 3 to 4 times daily. PR 100 to 200 mg 3 to 4 times daily.

PR 100 mg 3 to 4 times daily.

General Advice

• Do not use oral route with vomiting.
• Use Z-track technique for IM administration.

Storage/Stability

Avoid exposure to light; store at room temperature. Avoid freezing injectable.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Hypotension (after injection).

CNS

Mood depression; disorientation; headache; drowsiness; opisthotonos; dizziness; seizures; coma; Parkinson-like symptoms.

EENT

Blurred vision.

GI

Diarrhea.

Hematologic

Blood dyscrasias.

Hepatic

Jaundice.

Miscellaneous

Local pain, burning, stinging, redness and swelling (after injection); hypersensitivity reactions; muscle cramps.

Precautions

Pregnancy

Safety not established.

Lactation

Undetermined.

Hypersensitivity

Has been reported; discontinue use of drug at first signs of sensitivity.

Patient Information

• Instruct patient that when used for motion sickness, medication should be taken 30 min before exposure to motion.
• Advise patient to report these symptoms to health care provider: dizziness, yellowing of skin or eyes, muscle cramps, abnormal movements.
• Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
• Advise patient that drug may cause drowsiness or dizziness and to use caution while driving or performing tasks requiring mental alertness.

Link to this page

Printable Version

Email Page

Add to my drug list